Radiobiological evaluation of the therapeutic effect of silver-111 for the ISOLPHARM project

Alberto Arzenton, Aurora Leso, Francesca Rana, Giulia Valli, Elena Delgrosso, Laura Cansolino, Cinzia Ferrari, Silva Bortolussi, Isabella Guardamagna, G. Baiocco, G. Grosso, Davide Serafini, Andrea Gandini, Valerio Di Marco, A. Donzella, E. Mariotti, M. Lunardon, Devid Maniglio, G. Bonomi, A. AndrighettoFrontiers in Nuclear Medicine 2026 · DOI

TL;DR

This paper presents the first radiobiological characterization of silver-111 ($^{111}$Ag), a promising "theranostic" radionuclide for targeted cancer therapy. By combining Monte Carlo dosimetry with cell survival assays, researchers demonstrated that $^{111}$Ag effectively kills cancer cells with a Relative Biological Effectiveness (RBE) significantly higher than standard gamma radiation.

What Problem Does This Paper Address?

Targeted Radionuclide Therapy (TRT) involves attaching a radioactive isotope to a molecule that specifically seeks out cancer cells, delivering a lethal dose of radiation while sparing healthy tissue. While isotopes like Lutetium-177 are currently making waves in the clinic, researchers are hunting for the next generation of "theranostics"—isotopes that can both treat (via beta or alpha emission) and be imaged (via gamma emission).

Silver-111 ($^{111}$Ag) is a prime candidate: it has a favorable half-life (7.45 days), medium-energy beta particles for therapy, and low-energy gammas suitable for SPECT imaging. However, $^{111}$Ag has historically been difficult to produce in high purity. The ISOLPHARM project aims to solve this using Isotope Separation OnLine (ISOL) technology. This paper provides the essential "ground truth" radiobiology needed before these new radiopharmaceuticals can move toward clinical trials.

Methods

The researchers conducted a series of in vitro experiments to see how $^{111}$Ag affects two different cancer types: UMR-106 (rat osteosarcoma) and LNCaP (human prostate cancer).

  • Dosimetry (The "How Much"): Because the radiation source is dissolved in the cell culture medium, calculating the actual dose absorbed by a tiny cell nucleus is complex. The team used the MIRD formalism and Geant4 Monte Carlo simulations to model the energy deposition at the cellular level.
  • Biological Assays (The "What Happens"):
    • Clonogenic Survival: The gold standard for measuring a cell's ability to reproduce after radiation.
  • Foci Analysis: Using fluorescent markers ($\gamma$-H2AX and 53BP1) to count actual double-strand breaks in DNA.
  • Micronuclei Assay: Measuring chromosomal damage that results in small "extra" nuclei.
  • Comparison: They compared $^{111}$Ag's effectiveness against standard Cobalt-60 ($^{60}$Co) gamma radiation to determine its Relative Biological Effectiveness (RBE).

Datasets

As an experimental biology paper, the "datasets" consist of primary experimental measurements:

  • Cell Lines: UMR-106 (bone cancer) and LNCaP (prostate cancer).
  • Simulated S-values: A library of energy deposition values calculated via Geant4 for specific cell geometries (e.g., 0.06 mGy/(Bq s) $\mu$m³ for a cell in a radioactive medium).
  • Activity Concentrations: Tested ranges from ~40 to 480 kBq/mL over 4- and 6-day exposure periods.

Key Insights and Ideas

  • The Dose-Rate Paradox: In a surprising twist, the UMR-106 (bone cancer) cells showed lower survival when the dose was delivered over a longer period (lower dose rate). Usually, cells repair better when radiation is spread out. The authors hypothesize that the lower dose rate might fail to trigger certain DNA repair pathways in this specific cell line, leading to "unnoticed" but lethal damage.
  • Linear vs. Quadratic: When fitting the data to the standard Linear-Quadratic (LQ) model, the quadratic term ($\beta$) was nearly zero. This suggests that $^{111}$Ag causes complex, "high-density" DNA damage that is difficult for cells to repair, behaving more like high-LET (Linear Energy Transfer) radiation than typical beta emitters.
  • Theranostic Potential: The study confirms that $^{111}$Ag's decay properties are not just good on paper; they translate into effective cell killing in a laboratory setting.

Key Results

  • Relative Biological Effectiveness (RBE): For UMR-106 cells, $^{111}$Ag had an RBE of 1.43 (at 10% survival) compared to $^{60}$Co. This means $^{111}$Ag is roughly 43% more effective at killing these cells than standard gamma rays for the same absorbed dose.
  • DNA Damage: Both cell lines showed a clear increase in micronuclei frequency (a sign of permanent genetic damage) as the absorbed dose increased, correlating well with the survival data.
  • Chemical Safety: Control experiments confirmed that the chemical toxicity of silver and palladium (a byproduct) was negligible; the observed cell death was purely radiological.

Limitations and Future Work

  • Unbound Isotope: In this study, the $^{111}$Ag was "free" in the medium. In a real clinical application, it would be chelated and attached to a targeting vector (like a PSMA inhibitor). Future work will need to test these "labeled" compounds.
  • Simplified Geometry: The Monte Carlo simulations assumed a generalized cell geometry. Real-world cell clusters or 3D spheroids might show different dosimetric profiles.
  • Production Scale: The study used small quantities produced in a research reactor. The full potential of $^{111}$Ag will only be realized once the SPES facility at LNL-INFN is fully operational, providing high-purity, carrier-free isotopes via the ISOL method.

Summary updated

Abstract

Introduction: The ISOLPHARM project has the aim of developing novel radiopharmaceuticals using the wide choice of radionuclides produced by Isotope Separation OnLine (ISOL) at LNL-INFN in the SPES facility, which is currently nearing completion. One of the most promising candidates for Targeted Radionuclide Therapy (TRT) is the beta-emitting radiometal silver-111, obtainable carrier-free irradiating a uranium carbide target with a proton beam and applying the ISOL technique. Until SPES will become fully operational, small quantities of silver-111 are produced by the TRIGA Mark II nuclear reactor hosted by the LENA facility of the University of Pavia to begin the preclinical research. The present work concerns the first radiobiological experiment involving silver-111. Methods: Different activity concentrations of the aforementioned radiometal are administered to the UMR-106 rat osteosarcoma and LNCaP human prostate cancer cell lines through the culture medium. The survival curves after four and six days of exposure, as well as the recurrence of foci of DNA repair proteins and micronuclei, are evaluated as a function of the absorbed dose and compared to the control cultures. According to the MIRD formalism, a dosimetric analysis is performed taking advantage of cellular S-values simulated with the Monte Carlo code Geant4 in a generalized cell geometry. This makes it possible to relate the experimental outcome, namely the surviving cells after the exposure cycles, to the absorbed dose in the cell nucleus or in the whole cell environment. Results and discussion The results show a difference in the response of the two cell lines, probably due to the thresholds of their DNA repair pathways, and highlight a possible weakness of the linear-quadratic model when applied to this kind of radiobiological studies.
BibTeX
@inproceedings{arzenton2026radiobiological,
  author = {Alberto Arzenton and Aurora Leso and Francesca Rana and Giulia Valli and Elena Delgrosso and Laura Cansolino and Cinzia Ferrari and Silva Bortolussi and Isabella Guardamagna and G. Baiocco and G. Grosso and Davide Serafini and Andrea Gandini and Valerio Di Marco and A. Donzella and E. Mariotti and M. Lunardon and Devid Maniglio and G. Bonomi and A. Andrighetto},
  title = {{Radiobiological evaluation of the therapeutic effect of silver-111 for the ISOLPHARM project}},
  booktitle = {Frontiers in Nuclear Medicine},
  year = {2026},
  doi = {10.3389/fnume.2026.1773638},
}
Figure